LG Chem said its Chinese partner company Transthera Bioscience obtained the Chinese National Medical Products Administration (NMPA)’s authorization to conduct a phase 2 trial of LC510255, an autoimmune disease treatment in patients with atopic dermatitis.In April last year, LG Chem signed a licensin
Boryung Pharmaceutical said it would open the first Care In Space (CIS) Challenge, a global competition event to find technologies and solutions for human health in space.Boryung leads the CIS challenge in collaboration with Axiom Space, an American human spaceflight services provider, and Starbust,
GC Cell said that it acquired a 100 percent stake in BioCentriq, an American cell and gene therapy contract development and manufacturing organization (CDMO) company, together with GC.The acquisition follows the merger completion of GC Cell and GC Labcell last November.BioCentriq, a subsidiary of th
Eliquis (ingredient: apixaban), sold by BMS and Pfizer, recently added cancer-associated venous thromboembolism (VTE) treatment in approval conditions, the government said.The Ministry of Food and Drug Safety changed the clause of the “precautions for use” in approval conditions for Eliquis late las
Bridge Biotherapeutics said it signed an exclusive license-in agreement with Shaperon for its GPCR19 (G protein-coupled receptor 19) agonist, coded BBT-209, to develop a novel therapy for idiopathic pulmonary fibrosis (IPF).Under the accord, Bridge Bio will make an upfront payment of about 2 billion
Hugel said it obtained a product license for Persnica, a hyaluronic acid (HA) filler, from China’s National Medical Products Administration (NMPA) last Friday.According to the company, the global non-surgical-centered medical aesthetics industry continues to grow rapidly. China is showing particular
Daewoong Pharmaceutical is soon to apply for a phase 2 trial of DWN12088, a pulmonary fibrosis treatment, in the U.S.Daewoong aims to develop it as the nation’s next novel medicine, after fexuprazan and enavogliflozin.On Tuesday, industry sources said that Daewoong planned to submit an Investigation
Huinno said it signed a distribution contract with Yuhan Corp. for Memo Patch, an electrocardiogram monitoring service, in Korea.The accord follows the Ministry of Health and Welfare's recent amendment to reimbursement regulations, which increased the insurance coverage of Holter Monitoring for ECG
Edwards Lifesciences Korea said Monday that it has appointed Kwon Chang-seop, the head of the clinical care and vascular business unit, as its new CEO.Kwon is a financial planning and business development expert with more than 20 years of experience in the pharmaceutical industry, including MSD Kore
Despite the outward growth of the Korean biopharmaceutical industry, it has yet to develop new global blockbuster drugs.An expert has stressed that the sector could realize such goals only when it strengthens cooperation between bio clusters, develops more sophisticated regulatory systems, and inves
Human epidermal growth factor receptor (HER) 2 inhibitors, known to be effective in treating brain metastasis in HER2 positive breast cancer, are expected to compete in the Korean market in earnest.On Thursday, the Ministry of Food and Drug Safety approved a phase 3 HER2CLIMB-05 study of Tukysa (tuc
Astellas Pharma, which is transforming into an anti-cancer drug developer, said its antibody-drug conjugate (ADC) Padcev (ingredient: enfortumab vedotin) received the first approval in Europe.On Wednesday, Astellas announced that the European Commission authorized Padcev as monotherapy to treat adul
Korean pharmaceutical companies released polynucleotides (PN)-based intra-articular injections, heating the market competition.Intra-articular injections are biomaterials for tissue repair, mainly made of PN extracted from the DNA of fish such as salmon and trout.When injected into the knee joint of
The government will likely approve the nation’s third pure botulinum toxin product after Merz's Xeomin and Medytox's Coretox, pharmaceutical market sources said Thursday.Pure botulinum toxin has removed unnecessary complexing proteins through a new purification technology.According to industry insid
HLB Science, a subsidiary of HLB Global, listed on the tertiary stock market Konex, said that it has selected Shinhan Investment Corp. as the lead manager for its moving to the secondary bourse, Kosdaq.The company is a peptide-based new drug development company established in 2016 by Professor Park
Sanofi’s Dupixent (dupilumab), the first approved biological drug for treating atopic dermatitis (AD), proved excellent efficacy and long-term safety through a four-year study, data that improved quality of life, and post-marketing surveillance in Japan.At the American Academy of Dermatology (AAD) 2
LG Chem has enhanced the product lineup of human growth hormone injection Eutropin Pen.The Ministry of Food and Drug Safety granted the permit for Eutropin S Pen Inj. (ingredient: somatropin, recombinant human growth hormone) for the treatment of pediatric growth failure.Eutropin S Pen Inj. strength
Roche’s new spinal muscular atrophy (SMA) oral treatment Evrysdi (ingredient: risdiplam) proved the benefit of convenience and cost reduction for patients through new data.However, the discussion over reimbursement for Evrysdi has dragged on for over one year and a half since the drug’s arrival in K
Shionogi, a Japanese pharmaceutical company developing Covid-19 treatment S-217622 jointly with Ildong Pharmaceutical, said the recent controversy over the treatment’s potential harm in an animal study would not affect the drug approval.Earlier, Japanese news reports said that the company’s investig
HK inno.N said Thursday that it has obtained product approval from China's National Medical Products Administration (NMPA) for K-CAB (ingredient: tegoprazan), a gastroesophageal reflux disease (GERD).The indication approved in China is for erosive esophagitis.The approval comes after HK inno.N signe